Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

3.920 -0.110 (-2.73%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Volume	277,557
Open	4.050
Bid (Size)	3.880 (100)
Ask (Size)	3.940 (3,100)
Prev. Close	4.030
Today's Range	3.860 - 4.058
52wk Range	3.890 - 8.770
Shares Outstanding	113,793,338
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

December 23, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

November 19, 2025

From Precision BioSciences, Inc.

Via Business Wire

Performance

YTD	-4.4%	-4.4%
1 Month	-19.3%	-19.3%
3 Month	-33.3%	-33.3%
6 Month	-18.8%	-18.8%
1 Year	-12.9%	-12.9%

More News

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

November 10, 2025

From Precision BioSciences, Inc.

Via Business Wire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

November 10, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss ↗

November 03, 2025

Via Chartmill

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Precision BioSciences, Inc.

Via Business Wire

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

October 31, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

October 14, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

October 09, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

October 07, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

September 30, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

September 12, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

September 08, 2025

From Precision BioSciences, Inc.

Via Business Wire

DTIL Revenue Drops 99% ↗

August 07, 2025

Via The Motley Fool

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

August 06, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

August 04, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

July 23, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

July 16, 2025

From Precision BioSciences, Inc.

Via Business Wire

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’ ↗

June 25, 2025

Via Stocktwits

Discover the top movers in Wednesday's pre-market session. ↗

June 25, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 25, 2025

Via Benzinga

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

June 25, 2025

From Precision BioSciences, Inc.

Via Business Wire

Frequently Asked Questions

Is Precision BioSciences, Inc. - Common Stock publicly traded?

Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.

What exchange does Precision BioSciences, Inc. - Common Stock trade on?

Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?

The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market

What is the current price of Precision BioSciences, Inc. - Common Stock?

The current price of Precision BioSciences, Inc. - Common Stock is 3.920

When was Precision BioSciences, Inc. - Common Stock last traded?

The last trade of Precision BioSciences, Inc. - Common Stock was at 01/09/26 04:00 PM ET

What is the market capitalization of Precision BioSciences, Inc. - Common Stock?

The market capitalization of Precision BioSciences, Inc. - Common Stock is 446.07M

How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?

Precision BioSciences, Inc. - Common Stock has 446M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.